This page shows what was measured, who it was measured in, and what that does not settle.
What Candesartan Cilexetil does in the body
Hypertension
From the FDA-approved label: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathways for angiotensin II synthesis.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · R85M2X0D68 · read 2026-08-29
Its recorded molecular formula is C33H34N6O6, weighing 610.67.
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 112 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Focus
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Cholesterol
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Focus
cognitive assessment trail making test part b; cognitive assessment forward digit span test
Healthy ageing
mortality
Blood sugar
metabolic profiles including lipid profile and blood glucose
Cholesterol
metabolic profiles including lipid profile and blood glucose
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
△ Only a number moved
1 registered test measure.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.
✗ The study did not show it
Who was studied
NCT00741585
How many people
21983
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
All-cause mortality
✗ The study did not show it
Who was studied
NCT02735707
How many people
20000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
All-cause stroke (including fatal and non-fatal stroke)
✗ The study did not show it
Who was studied
NCT05169021
How many people
15000
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
The composite of; Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke.
✗ The study did not show it
Who was studied
NCT00468923
How many people
12705
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
✗ The study did not show it
Who was studied
NCT00000620
How many people
10251
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Cardiovascular mortality or hospitalisation due to congestive heart failure
✗ The study did not show it
Who was studied
NCT00634400
How many people
6268
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. 2 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.11 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
blood pressure
home blood pressure in the early morning
plasma nt pro bnp concentration
urinary tgf beta 1
serum angiotensin ii
urinary albumin
urinary carboxymethyllysine
metabolic profiles including lipid profile and blood glucose
degree of inflammation in stenotic aortic valves
n terminal pro b type natriuretic peptide biomarker
and 1 more.
Meaningful
Things that change how a life goes, not only a number.
mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (28)
recurrence of atrial fibrillation
ace and ace2 activities in monocytes
lv mass index
la volume index
changes in homa index value
basement membrane thickness
mesangial expansion
b type natriuretic peptides level
change in sitting bp
kidney volume measured by mri
morpho functional left ventricle characteristics
metabolic profile
tolerance of the medication
cognitive assessment trail making test part b
cognitive assessment forward digit span test
tissue type plasminogen activator antigen response
plasminogen activator inhibitor 1 response
interleukin 6 response
interleukin 8 response
interleukin 10 response
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 9 hours hours
Read from the label, which states: “The elimination half-life of candesartan is approximately 9 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The antihypertensive effects of candesartan cilexetil were evaluated in hypertensive children 1 to < 17 years of age in randomized, double-blind clinical studies [see Clinical Studies ( 14.1 )].”
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Candesartan cilexetil can cause fetal harm when administered to a pregnant woman.”
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-30
On people who are breastfeeding, the label states: “It is not known whether candesartan is excreted in human milk, but candesartan has been shown to be present in rat milk.”
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3, S6.
No source is stored against this line.
What is in the pack
Sold as tablet, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Candesartan Cilexetil appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 3412 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
acute kidney injury — 608 reaction mentions
hypotension — 544 reaction mentions
hyperkalaemia — 388 reaction mentions
dizziness — 365 reaction mentions
fall — 331 reaction mentions
hyponatraemia — 324 reaction mentions
renal failure acute — 237 reaction mentions
syncope — 211 reaction mentions
confusional state — 205 reaction mentions
blood pressure increased — 199 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
65 products list this as an active ingredient in the United States drug directory. 45 of them contain it and nothing else.
FDA National Drug Code directory · 33342-132 · read 2026-08-29
They are sold as powder and tablet, taken oral.
FDA National Drug Code directory · 33342-132 · read 2026-08-29
The regulator's established pharmacologic class for it is angiotensin 2 receptor antagonists [moa] and angiotensin 2 receptor blocker [epc].
FDA National Drug Code directory · 33342-132 · read 2026-08-29
19 published labels name it as an active ingredient. 13 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-29
Candesartan is oral at 3 DOSAGE FORMS AND STRENGTHS 16 mg are pink, circular, biconvex, uncoated tablets, debossed with “ML 54” on one side and breakline on other side. 32 mg are pink, circular, biconvex, uncoated tablets, debossed with “ML 5…, recorded as fda label in effect 2025-11-26 in the United States.
US prescribing information · 880f685f-be01-42f4-9e76-ebd1fcfb1f77 · read 2026-08-30
Recorded price in US: 0.4788–0.55281 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 26 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Candesartan Cilexetil studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Candesartan Cilexetil are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
9 documents were read for this substance.
RNAWiki source record
9 of them state the same halfLife, and they agree.
RNAWiki source record
9 of them state the same bioavailability, and they agree.
RNAWiki source record
9 of them state the same proteinBinding, and they agree.
RNAWiki source record
9 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
R85M2X0D68
RxNorm concept
153822
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
16 approved applications cover products containing this substance. The earliest was NDA020838, approved 19980604 to ANI PHARMS.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Candesartan Cilexetil's largest trial (40000 people) and its longest (14 years) measure?
40000 people in Candesartan Cilexetil's largest registered study, 14 years in its longest registered window, measuring Mortality (all causes). ClinicalTrials.gov · 2026-09-01
36 phase3, 33 phase4, 25 phase2, 17 phase1, 10 na or unstated, 5 na, 3 early phase1; NCT00150631; 2014-12. Last human test completed 2024, NCT05328635.
Interpretation These counts include studies where Candesartan Cilexetil was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase3
36
phase4
33
phase2
25
phase1
17
na or unstated
10
na
5
2 more recorded rows
early phase1
3
Last recorded human testNCT05328635
2024-09-01
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Candesartan Cilexetil shown lifespan?
292 mice; cohorts C2016; cohort rows are the workbook's own printed values; no median, percent change or survival statistic is derived from the per-animal data
Show the evidence
ITP cohortC2016
candesartan cilexetil; 30.0; 8.0 months; f, m; ITP_C2016_Lifespan.xlsx
recorded 2026-09-04 · last checked 2026-09-04
Q5
10 of Candesartan Cilexetil's trials stopped: futility/efficacy, accrual/recruitment, funding/business, other?
futility/efficacy (2), accrual/recruitment (3), funding/business (2) and other (3): Candesartan Cilexetil's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Difficulties in completing the required sample size"; 10 of 125 registered studies
Show the evidence
Trial
NCT00319202
terminated; "Difficulties in completing the required sample size"
NCT00843154
terminated; "Insufficient enrollment"
NCT00930995
withdrawn; "Not Awarded"
NCT01794455
terminated; "Enrollment difficulties"
NCT01938664
terminated; "Results of interim efficacy analysis showed results were not promising."
NCT02047019
withdrawn; "GPDC decided to terminate the study"
4 further recorded trials
NCT03688633
terminated; "Patient Recruitment Failure"
NCT04430959
withdrawn; "The reason the study was withdrawn was due to lack of funds. In addition, the PI is moving to a different institution and it would not be feasible to proceed with the study under these circumstances."
NCT04606563
terminated; "DSMC recommendation due to futility"
NCT05122182
terminated; "Withdrawal of funding support from the trial funder."
recorded 2026-09-01 · last checked 2026-09-04
Q6
Mouse studies of Candesartan Cilexetil used 30 ppm — over how long?
studies of Candesartan Cilexetil used the recorded amount. clinicaltrials.gov+jax-mpd-itp · 2026-09-04
21 recorded entries; mouse, human; also "30 ppm", "candesartan 8 mg", "Candesartan Cilexetil 32mg"
Candesartan Cilexetil's half-life is 9 hours — which schedules were studied?
9 hours, the half-life Candesartan Cilexetil's label states. openfda-label · 7eb297cb-ef1b-44e0-a49d-03727100579e · 2026-08-30
bioavailability 15% %.
Show the evidence
half life
9 hours hours; The elimination half-life of candesartan is approximately 9 hours.
bioavailability
15% %; Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
recorded 2026-08-30 · last checked 2026-09-04
Q8
Which of ace and ace2 activities in monocytes, b type natriuretic peptides level and basement membrane thickness did Candesartan Cilexetil's trials measure?
ace and ace2 activities in monocytes, b type natriuretic peptides level and basement membrane thickness lead 40 outcome terms across Candesartan Cilexetil's trials. ClinicalTrials.gov · 2026-09-01
ace and ace2 activities in monocytes, home blood pressure in the early morning, lv mass index, la volume index, plasma nt pro bnp concentration and changes in homa index value follow.
Show the evidence
blood pressure
1
mortality
1
recurrence of atrial fibrillation
1
ace and ace2 activities in monocytes
1
home blood pressure in the early morning
1
lv mass index
1
14 more recorded rows
la volume index
1
plasma nt pro bnp concentration
1
changes in homa index value
1
urinary tgf beta 1
1
serum angiotensin ii
1
urinary albumin
1
urinary carboxymethyllysine
1
basement membrane thickness
1
mesangial expansion
1
b type natriuretic peptides level
1
change in sitting bp
1
metabolic profiles including lipid profile and blood glucose
1
kidney volume measured by mri
1
morpho functional left ventricle characteristics
1
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which of Candesartan Cilexetil's 9 ongoing trials reports first?
All-cause mortality; Candesartan concentration in blood serum (area under curve (AUC)); latest 2031-07
Show the evidence
Trial
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
NCT03460327
"Bariatric Surgery and Pharmacokinetics of Candesartan"; n 12; "Candesartan concentration in blood serum (area under curve (AUC))"; 2026-10
NCT03583866
"Adiposity and Endothelin Receptor Function"; n 25; "Percentage Change in Flow-Mediated Dilation (FMD)"; 2026-01
NCT03770936
"Effect of Some Drugs on Liver Fibrosis"; n 45; "Change in Fibroscan or APRI score"; 2027-11
NCT05321875
"Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)"; n 320; "Proportion of participants that progress to either a LVEF or LVEDV deterioration of ≥10% with respect to the baseline value at the end of follow-up as measured by MRI"; 2026-06-02
NCT05826912
"Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury"; n 672; "Change in Glasgow Outcome Scale-Extended (GOSE 2-Way)"; 2029-08-31
3 further recorded trials
NCT07547878
"Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)"; n 64; "On-study retention rate at 6 months"; 2029-03-31
NCT07655440
"Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)"; n 120; "Change in Tinnitus Functional Index (TFI) Score"; 2031-07
NCT07687160
"SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy"; n 30; "PRIMARY OUTCOME: Recruitment Rate of Randomized Participants per Month"; 2028-02
recorded 2026-09-01 · last checked 2026-09-04
Q10
Which running trial of Candesartan Cilexetil could settle lifespan?
NCT02735707 measures All-cause mortality, reading out 2028-02.
1 open trial; n 20000; "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"
Show the evidence
TrialNCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
Q11
Which 60 trials of Candesartan Cilexetil posted no result?
Posted no result
60 of 60 completed trials
Registrations
NCT00587470, NCT00634309, NCT00634400, NCT00634712, NCT00320970 and NCT00130975, and 54 more
Completion dates
oldest 2001-08; newest 2024-09-01
Show the evidence
Trial
NCT00587470
2001-08
NCT00634309
2003-05
NCT00634400
2003-05
NCT00634712
2003-05
NCT00320970
2004-09
NCT00130975
2005-09
14 further recorded trials
NCT00227318
2005-10
NCT00282178
2006-04
NCT00242346
2006-12
NCT00310778
2007-03
NCT00383929
2007-10
NCT00005520
2008-01
NCT01289132
2008-07
NCT00905333
2008-11
NCT00775840
2008-12
NCT00620178
2009-02
NCT00538486
2009-06
NCT00844324
2009-06
NCT00184587
2009-12
NCT00400582
2010-04
Q12
At the median, Candesartan Cilexetil's trials enrolled 123.5 people — anything larger?
Median enrolment
123.5
Largest enrolment
40000
Registered trials counted
124
Q13
What do 3412 spontaneous reports say about Candesartan Cilexetil — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Candesartan Cilexetil appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 3412 reaction mentions were counted: acute kidney injury 608; hypotension 544; hyperkalaemia 388; dizziness 365. open-targets-adr · CHEMBL1014 · 2026-06-24
Show the evidence
acute kidney injury
608
hypotension
544
hyperkalaemia
388
dizziness
365
fall
331
hyponatraemia
324
4 more recorded rows
renal failure acute
237
syncope
211
confusional state
205
blood pressure increased
199
recorded 2026-06-24 · last checked 2026-09-04
Q14
Was Candesartan Cilexetil studied with exercise?
exercise is named in Candesartan Cilexetil's label sentences: "The trial was neutral or negative regarding the primary end-point in four (47 patients) of the six studies (MACH-1 trial of mibefradil, REACH trial of bosentan, CASCO trial of calcium sensitizer, ecadotril trial of neutral endopeptidase inhibitor) and positive in two (23 patients) (ICARUS Israel…" openfda-label+europepmc · 2001-03-01
1 recorded statement; exercise
Show the evidence
exercise
The trial was neutral or negative regarding the primary end-point in four (47 patients) of the six studies (MACH-1 trial of mibefradil, REACH trial of bosentan, CASCO trial of calcium sensitizer, ecadotril trial of neutral endopeptidase inhibitor) and positive in two (23 patients) (ICARUS Israel carvedilol study, exercise study of candesartan cilexetil).
recorded 2001-03-01 · last checked 2026-09-04
Q15
What is recorded about Candesartan Cilexetil and NAD+?
"(1) Vascular endothelium-dependent relaxation with acetylcholine in KKAy mice was improved by azilsartan treatment compared to candesartan cilexetil; (2) the ratio of Ser1177/Thr495 phosphorylation of eNOS was impaired in KKAy and was effectively restored by azilsartan; (3) anomalies in the expression levels of monocyte chemotactic…" — where Candesartan Cilexetil and NAD+ appear together. Europe PMC · pathway abstract search · 2014-01-31
NAD+; PMID 24485356
Show the evidence
NAD+PMID 24485356
"(1) Vascular endothelium-dependent relaxation with acetylcholine in KKAy mice was improved by azilsartan treatment compared to candesartan cilexetil; (2) the ratio of Ser1177/Thr495 phosphorylation of eNOS was impaired in KKAy and was effectively restored by azilsartan; (3) anomalies in the expression levels of monocyte chemotactic protein 1 (MCP1), F4/80, NAD(P)H oxidase (Nox) 2, and Nox4 of the…"
recorded 2014-01-31 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · NIA ITP via the JAX Mouse Phenome Database · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.